Related Experiment Videos
Postprandial lipoprotein clearance in type 2 diabetes: fenofibrate effects
E Cavallero1, A Piolot, B Jacotot
1Service de Médecine Interne, Nutrition et Métabolisme de Lipides, Hôpital Henri Mondor, Créteil, France.
Diabete & Metabolisme
|April 1, 1995
Summary
Type 2 diabetes patients often have lipid intolerance, leading to increased cardiovascular risk. Fenofibrate treatment improved both fasting and postprandial lipid levels, suggesting a potential therapeutic benefit.
Area of Science:
- Endocrinology
- Metabolic Syndrome
- Cardiovascular Disease Research
Background:
- Type 2 diabetes is associated with lipoprotein abnormalities, including elevated triglycerides and low HDL cholesterol, increasing cardiovascular disease (CVD) risk.
- Fasting lipid levels may not fully reflect the atherogenic lipid profile in diabetic patients, as postprandial lipemia is often impaired.
- Independent predictors of cardiovascular mortality in diabetic and glucose-intolerant individuals include fasting triglycerides and central obesity.
Purpose of the Study:
- To investigate postprandial lipemia in Type 2 diabetes patients.
- To assess the impact of fenofibrate on lipid metabolism and lipoprotein abnormalities in Type 2 diabetes.
- To identify atherogenic changes in plasma lipoproteins during the postprandial state.
Main Methods:
- Assessment of postprandial lipemia, including triglyceride levels and lipoprotein composition, in Type 2 diabetic patients.
- Evaluation of fasting and postprandial lipid profiles before and after fenofibrate treatment.
- Analysis of lipoprotein abnormalities and their association with cardiovascular risk factors.
Main Results:
- Lipid intolerance, characterized by increased postprandial triglycerides and delayed clearance, was prevalent in Type 2 diabetes patients.
- Fenofibrate treatment demonstrated improvements in fasting lipid levels.
- Preliminary findings indicate fenofibrate also ameliorates postprandial lipemia and associated atherogenic lipoprotein changes.
Conclusions:
- Postprandial lipemia is a significant indicator of atherogenic lipoprotein changes in Type 2 diabetes.
- Fenofibrate treatment shows promise in improving both fasting and postprandial lipid profiles in Type 2 diabetes.
- Targeting postprandial dyslipidemia may be crucial for reducing cardiovascular risk in diabetic populations.